Biosimilar therapies in inflammatory bowel disease: should we care about patient profile?

Tu1348 Biosimilar Infliximab in Inflammatory Bowel Diseases: First Interim Results From a Prospective Nationwide Observational Cohort

(2015) Krisztina Gecse et al.   GASTROENTEROLOGY

Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort

(2015) Johan Burisch et al.   INFLAMMATORY BOWEL DISEASES

The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper

(2014) Gionata Fiorino et al.   AUTOIMMUNITY REVIEWS

Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease

(2014) Vito Annese et al.   DIGESTIVE AND LIVER DISEASE

Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization

(2014) Silvio Danese et al.   Journal of Crohns & Colitis

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)

(2013) Silvio Danese et al.   Journal of Crohns & Colitis

Joint position statement by "Sociedad Española de Patología Digestiva" (Spanish Society of Gastroenterology) and "Sociedad Española de Farmacología" (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease

(2013) Federico Argüelles-Arias et al.   REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS

Mucosal healing—EXTENDing our knowledge in Crohn's disease

(2012) Silvio Danese et al.   Nature Reviews Gastroenterology & Hepatology

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials

(2008) Laurent Peyrin–Biroulet et al.   Clinical Gastroenterology and Hepatology